Lymphedema Rates Following Axillary Lymph Node Dissection With and Without Immediate Lymphatic Reconstruction: A Prospective Trial.

Breast cancer Breast cancer-related lymphedema (BCRL) LYMPHA Lymphaticovenous anastomosis Lympho-venous bypass Radiation

Journal

Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840

Informations de publication

Date de publication:
02 Jul 2024
Historique:
received: 11 04 2024
accepted: 10 06 2024
medline: 3 7 2024
pubmed: 3 7 2024
entrez: 2 7 2024
Statut: aheadofprint

Résumé

Immediate lymphatic reconstruction (ILR) has been proposed to decrease lymphedema rates. The primary aim of our study was to determine whether ILR decreased the incidence of lymphedema in patients undergoing axillary lymph node dissection (ALND). We conducted a two-site pragmatic study of ALND with or without ILR, employing surgeon-level cohort assignment, based on breast surgeons' preferred standard practice. Lymphedema was assessed by limb volume measurements, patient self-reporting, provider documentation, and International Classification of Diseases, Tenth Revision (ICD-10) codes. Overall, 230 patients with breast cancer were enrolled; on an intention-to-treat basis, 99 underwent ALND and 131 underwent ALND with ILR. Of the 131 patients preoperatively planned for ILR, 115 (87.8%) underwent ILR; 72 (62.6%) were performed by one breast surgical oncologist and 43 (37.4%) by fellowship-trained microvascular plastic surgeons. ILR was associated with an increased risk of lymphedema when defined as ≥10% limb volume change on univariable analysis, but not on multivariable analysis, after propensity score adjustment. We did not find a statistically significant difference in limb volume measurements between the two cohorts when including subclinical lymphedema (≥5% inter-limb volume change), nor did we see a difference in grade between the two cohorts on an intent-to-treat or treatment received basis. For all patients, considering ascertainment strategies of patient self-reporting, provider documentation, and ICD-10 codes, as a single binary outcome measure, there was no significant difference in lymphedema rates between those undergoing ILR or not. We found no significant difference in lymphedema rates between patients undergoing ALND with or without ILR.

Sections du résumé

BACKGROUND BACKGROUND
Immediate lymphatic reconstruction (ILR) has been proposed to decrease lymphedema rates. The primary aim of our study was to determine whether ILR decreased the incidence of lymphedema in patients undergoing axillary lymph node dissection (ALND).
METHODS METHODS
We conducted a two-site pragmatic study of ALND with or without ILR, employing surgeon-level cohort assignment, based on breast surgeons' preferred standard practice. Lymphedema was assessed by limb volume measurements, patient self-reporting, provider documentation, and International Classification of Diseases, Tenth Revision (ICD-10) codes.
RESULTS RESULTS
Overall, 230 patients with breast cancer were enrolled; on an intention-to-treat basis, 99 underwent ALND and 131 underwent ALND with ILR. Of the 131 patients preoperatively planned for ILR, 115 (87.8%) underwent ILR; 72 (62.6%) were performed by one breast surgical oncologist and 43 (37.4%) by fellowship-trained microvascular plastic surgeons. ILR was associated with an increased risk of lymphedema when defined as ≥10% limb volume change on univariable analysis, but not on multivariable analysis, after propensity score adjustment. We did not find a statistically significant difference in limb volume measurements between the two cohorts when including subclinical lymphedema (≥5% inter-limb volume change), nor did we see a difference in grade between the two cohorts on an intent-to-treat or treatment received basis. For all patients, considering ascertainment strategies of patient self-reporting, provider documentation, and ICD-10 codes, as a single binary outcome measure, there was no significant difference in lymphedema rates between those undergoing ILR or not.
CONCLUSION CONCLUSIONS
We found no significant difference in lymphedema rates between patients undergoing ALND with or without ILR.

Identifiants

pubmed: 38955992
doi: 10.1245/s10434-024-15715-w
pii: 10.1245/s10434-024-15715-w
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

© 2024. Society of Surgical Oncology.

Références

Forte AJ, Sisti A, Huayllani MT, et al. Lymphaticovenular anastomosis for breast cancer-related upper extremity lymphedema: a literature review. Gland Surg. 2020;9(2):539–44.
doi: 10.21037/gs.2020.03.41 pubmed: 32420289
Boccardo F, Casabona F, De Cian F, et al. Lymphedema microsurgical preventive healing approach: a new technique for primary prevention of arm lymphedema after mastectomy. Ann Surg Oncol. 2009;16:703–8.
doi: 10.1245/s10434-008-0270-y pubmed: 19139964
Ozmen T, Lazaro M, Zhou Y, Vinyard A, Avisar E. Evaluation of simplified lymphatic microsurgical preventing healing approach (S-LYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection. Ann Surg. 2019;270(6):1156–60.
doi: 10.1097/SLA.0000000000002827 pubmed: 29794843
McEvoy MP, Gomberawalla A, Smith M, et al. The prevention and treatment of breast cancer- related lymphedema: a review. Front Oncol. 2022;6(12):1–12.
Fraser Hill WK, Deban M, Platt A, Rojas-Garcia P, Jost E, Temple-Oberle C. Immediate Lymphatic reconstruction during axillary node dissection for breast cancer: a systematic review and meta-analysis. Plast Reconstr Surg Glob Open. 2022; 9;10(5):e4291.
Mayrovitz HN. Noninvasive measurements of breast cancer-related lymphedema. Cureus. 2021; 22;13(11):e19813.
Norman SA, Miller LT, Erikson HB, Norman MF, McCorkle R. Development and validation of a telephone questionnaire to characterize lymphedema in women treated for breast cancer. Phys Ther. 2001;81(6):1192–205.
doi: 10.1093/ptj/81.6.1192 pubmed: 11380275
Hortobagyi GN, Connolly JL, D’Orsi CJ et al. Breast in Alin MB, et al. editors. AJCC Cancer Staging Manual. 8th Ed. New York: Springer; 2017.
Jakub JW, Baloul MS. Prophylactic Lympho Venous Bypass Following Axillary Lymph Node Dissection Simple LYMPHA. The American Society of Breast Surgeons | ASBrS Video Library, Member Created Content.
Feldman S, Bansil H, Ascherman J, et al. Single institution experience with lymphatic microsurgical preventive healing approach (LYMPHA) for the primary prevention of lymphedema. Ann Surg Oncol. 2015;22(10):3296–301.
doi: 10.1245/s10434-015-4721-y pubmed: 26202566
Levy AS, Murphy AI, Ishtihar S, et al. Lymphatic microsurgical preventive healing approach for the primary prevention of lymphedema: a 4-year follow-up. Plast Reconstr Surg. 2023;151(2):413–20.
doi: 10.1097/PRS.0000000000009857 pubmed: 36696330
Coriddi M, Dayan J, Bloomfield E, et al. Efficacy of immediate lymphatic reconstruction to decrease incidence of breast cancer-related lymphedema: preliminary results of randomized controlled trial. Ann Surg. 2023;278(4):630–7.
doi: 10.1097/SLA.0000000000005952 pubmed: 37314177
Mori Tal, Lustman Alexander, Katz-Leurer Michal. Self-measurement of upper extremity volume in women post-breast cancer: reliability and validity study. Physiother Theory Pract. 2015;31(4):283–7.
doi: 10.3109/09593985.2014.994249 pubmed: 25539094
Rafn BS, McNeely ML, Camp PG, Midtgaard J, Campbell KL. Self-measured arm circumference in women with breast cancer is reliable and valid. Phys Ther. 2019;99(2):240–53.
doi: 10.1093/ptj/pzy117 pubmed: 30289500

Auteurs

James W Jakub (JW)

Division of Surgical Oncology, Mayo Clinic, Jacksonville, FL, USA. Jakub.james@mayo.edu.

Judy C Boughey (JC)

Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.

Tina J Hieken (TJ)

Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.

Mara Piltin (M)

Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.

Antonio Jorge Forte (AJ)

Division of Plastic Surgery, Mayo Clinic, Jacksonville, FL, USA.

Aparna Vijayasekaran (A)

Division of Plastic Surgery, Mayo Clinic, Rochester, MN, USA.

Monica Mazur (M)

Division of Surgical Oncology, Mayo Clinic, Jacksonville, FL, USA.

Jenna Sturz (J)

Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.

Kim Corbin (K)

Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.

Laura Vallow (L)

Department of Radiation Oncology, Mayo Clinic, Jacksonville, FL, USA.

Jeffrey E Johnson (JE)

Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.

Mary Mrdutt (M)

Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.

Vahe Fahradyan (V)

Division of Plastic Surgery, Mayo Clinic, Rochester, MN, USA.

Zhuo Li (Z)

Department of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL, USA.

Sophia Blumenfeld (S)

Department of Clinical Trials and Biostatistics, Mayo Clinic, Jacksonville, FL, USA.

Amy Degnim (A)

Division of Breast and Melanoma Surgical Oncology, Mayo Clinic, Rochester, MN, USA.

Kathleen J Yost (KJ)

Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA.

Andrea Cheville (A)

Department of Physical Medicine and Rehabilitation, Mayo Clinic, Rochester, MN, USA.

Sarah A McLaughlin (SA)

Division of Surgical Oncology, Mayo Clinic, Jacksonville, FL, USA.

Classifications MeSH